SCHEMBL3014970

SCHEMBL3014970

Cc1cccc(-c2csc(N3CCN(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)c1C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.45
MAPT P10636 4/20 0.45
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
LMNA P02545 3/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
MAPK1 P28482 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
TSHR P16473 2/20 0.43
ALOX15 P16050 1/20 0.43
USP2 O75604 2/20 0.42
RECQL P46063 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH3A1 P30838 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
TP53 P04637 1/20 0.41
TDP1 Q9NUW8 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012852 0.92 AR (0.47) ARMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL3019200 0.92 MEN1 (0.47) ARMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL15671700 0.90 MAPT (0.50) MAPTALDH1A1SMN1; SMN2LMNAMEN1
SCHEMBL3003930 0.89 MAPT (0.46) ARMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL3000574 0.89 ALDH1A1 (0.47) ARMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL3015116 0.89 KMT2A (0.52) ARMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL3006508 0.88 RAB9A (0.49) ARMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL3004747 0.88 AR (0.43) ARMAPTSMN1; SMN2LMNAMEN1
SCHEMBL3006370 0.87 MAPT (0.47) ARMAPTALDH1A1SMN1; SMN2LMNA
SCHEMBL3015386 0.87 SMN1; SMN2 (0.53) ARMAPTALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885MAPT 18/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.